Plné znění - 47/2014 Sb. m. s.

Sdělení o přijetí nového znění Přílohy I (Seznam zakázaných látek a metod - Mezinárodní standard) Mezinárodní úmluvy proti dopingu ve sportu

47/2014 Sb. m. s.

Sdělení

INFORMACE

47

XXXXXXX

Xxxxxxxxxxxx xxxxxxxxxxxx věcí,

kterým xx xxxx x xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx č. 58/2007 Xx. x. x. a x. 46/2008 Sb. m. x. x xxxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx č. 98/2013 Xx. x. s. x Mezinárodní xxxxxx xxxxx xxxxxxx xx xxxxxx

Xxxxxxxxxxxx zahraničních věcí xxxxxxx, že xxx 11. xxxxxxxxx 2013 xxxx xxxxxxxxx ředitelkou XXXXXX oznámeno xxxxxxxxx xxxxxx xxxxx Xxxxxxx X - Xxxxxxx xxxxxxxxxx xxxxx x xxxxx - Mezinárodní xxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx dopingu xx xxxxxx.¹⁾

X xxxxx zněním Xxxxxxx X xxxxxxxx xxxxxxx Parlament České xxxxxxxxx a prezident xxxxxxxxx podepsal xxxxxxx x přijetí xxxxx Xxxxxxx X Xxxxxx xxxxxxxxxx.

Xxxx xxxxx Přílohy X xxxxxxxxx x xxxxxxxx x xxxxxxx x xxxxxxx 34 xxxx. 3 Úmluvy xxx 1. xxxxx 2014 a xxxxx xxxx xxxxxxxxx x xxxxxxxx x xxx Xxxxxx xxxxxxxxx. Xxxx xxxxxx xxxxxx xxxxx Xxxxxxx X x xxxxxxxx xxxxxxxx xxxxxx xxxxx Přílohy X Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx ve xxxxxx xxxxxx xx 1. xxxxx 2013 x xxxxxxxxx xxx č. 98/2013 Sb. m. s.

Xxxxxxxx xxxxx Přílohy I x její xxxxxxx xx českého jazyka xx xxxxxxxxx xxxxxxxx.

¹⁾ Xxxxxxxxxxx úmluva xxxxx xxxxxxx ve xxxxxx xxxxxxx dne 19. xxxxx 2005 x Xxxxxx xxxx vyhlášena xxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.

XXXXXXXXXXX XXXXXX XXXXX XXXXXXX XX XXXXXX
Xxxxxxx X - Seznam xxxxxxxxxx látek a xxxxx - Mezinárodní xxxxxxxx
Xxxxx, 1. xxxxx 2014

XXXXXX ZAKÁZANÝCH XXXXX X METOD XXXXXXX XXX ROK 2014

SVĚTOVÝ XXXXXXXXXXXXX XXXXX

Xxxxxx xx 1. ledna 2014

Podle xxxxxx 4.2.2 Světového xxxxxxxxxxxxxxx xxxxxx všechny Xxxxxxxx xxxxx xxxxx xxxxxxxxxx za "Xxxxxxxxxx xxxxx" kromě látek xx xxxxxx S1, X2, S4.4, X4.5 x S6(a) x Xxxxxxxxxx xxxxx X1, X2 x X3.

XXXXX X XXXXXX XXXXXXXX XXXXX (XXX SOUTĚŽI X XXXX XXXXXX)

XXXXXXXX XXXXX

X0. XXXXXXXXXXX XXXXX

Xxxxxxxxx xxxxxxxxxxxxx xxxxx, xxxxx xxxx xxxxxxxx x xxxxxxxxxxxxx xxxxxxx Xxxxxxx x xxxx xxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. xxxxxx x xxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx xxxxxxx xxxx xx xxxxxxxx xxxxxxxxxx, xxxxxxxxxx xxxxx, látky xxxxxxxxx pouze xxx xxxxxxxxxxx xxxxxxx), je xxxxxxxx xxxxx.

X1. ANABOLICKÉ XXXXX

Xxxxxxxxxx xxxxx jsou xxxxxxxx.

1. ANDROGENNÍ XXXXXXXXXX XXXXXXXX (XXX):

(x) Xxxxxxxx* XXX, xxxxxxxxxx:

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3x,17β-xxxx); 1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (xxxx-4-xx-3β,17β-xxxx); xxxxxxxxxx; xxxxxxxx; xxxxxxx (androsta-1,4-dien-3,17-dion); danazol ([1,2]xxxxxx[4',5':2,3]xxxxxx-4-xx-20-xx-17α-xx); dehydrochlormethyltestosteron (4-chloro-17β-hydroxy-17α-methylandrosta-1,4-dien-3-on); xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; xxxxxxxxxxxxx (19-nor-pregna-4-en-17α-ol); fluoxymesteron; xxxxxxxxxx; xxxxxxxxx (17α-xxxxxx[1,2,5]xxxxxxxxxx[3',4':2,3]-5α-xxxxxxxxx-17β-xx); xxxxxxxxx; 4-xxxxxxxxxxxxxxxxxx (4,17β-dihydroxyandrost-4-en-3-on); xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxx; methandriol; xxxxxxxxxx (17β-xxxxxxx-2α,17α-xxxxxxxx-5α-xxxxxxxxx-3-xx); xxxxxxxxxxxxxx (17β-hydroxy-17α-methylestra-4,9-dien-3-on); xxxxxx-1-xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxxxx; xxxxxxxxxx (xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx); xxxxxxxxx; xxxxxxxxx; 19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; xxxxxxxxxxxxxx; xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxxx; oxymesteron; xxxxxxxxxx; xxxxxxxxxxx (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1'X-xxxxxxxx[3,4,:2,3]-5α-xxxxxxxxxx); xxxxxxxxx; stanozolol; stenbolon; 1-xxxxxxxxxxx (17β-hydroxy-5α-androst-1-en-3-on); xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18α-xxxx-19-xxx-17α-xxxxxx-4,9,11-xxxxx-3-xx); trenbolon (17β-xxxxxxxxxx-4,9,11-xxxxx-3-xx) x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

(x) Endogenní** XXX, xxxxx jsou xxxxxx xxxxxxxx:

Xxxxxxxxxxxxx (androst-5-en-3β,17β-diol), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), xxxxxxxxxxxxxxxxxx, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, DHEA), 3β-xxxxxxxxxxxxx-5-xx-17-xx), xxxxxxxxxxx x xxxxxx xxxxxxxxxx x xxxxxxx, xxx xx x omezením xxxxx xx ně:

5α-androstan-3α,17α-diol	5-androstendion (xxxxxxx-5-xx-3,17-xxxx)
5α-xxxxxxxxx-3α,17β-xxxx	xxx-xxxxxxxxxxxxxxxxxx
5α-xxxxxxxxx-3β,17α-xxxx	xxxxxxxxxxxxxx
5α-xxxxxxxxx-3β,17β-xxxx	xxxxxxxxxxxxxx
xxxxxxx-4-xx-3α,17α-xxxx	3α-xxxxxxx-5αxxxxxxxxx-17-xx
xxxxxxx-4-xx-3α,17β-xxxx	3β-xxxxxxx-5αxxxxxxxxx-17-xx
xxxxxxx-5-xx-3β,17α-xxxx	7α-xxxxxxx-XXXX
xxxxxxx-5-xx-3α,17α-xxxx	7β-xxxxxxx-XXXX
xxxxxxx-5-xx-3α,17β-xxxX	7-xxxx-XXXX
xxxxxxx-5-xx-3β,17α-xxxx	19-xxxxxxxxxxxxxx
4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3β,17β-xxxx)	19-xxxxxxxxxxxxxxxxx

Xxx xxxxx skupiny xxxx xxxxx:

* "xxxxxxxx" xx xxxxxxxx x xxxxx, xxxxxx xxxx xxxxxxxx přirozeně xxxxxxxxxxx.

** "xxxxxxxxx " xx xxxxxxxx k látce, xxxxxx tělo xxxxxxxx xxxxxxxxx xxxxxxxxx.

2. Xxxxxxx xxxxxxxxxx xxxxx, zahrnující:

Klenbuterol, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxx, xxxxxxx, xxxxxxxxxx, xxx xx s xxxxxxxx xxxxx na xx.

X2. XXXXXXXXX XXXXXXX, XXXXXXX XXXXXXX A XXXXXXXX XXXXX

Xxxxxxxxxxx xxxxx x xxxxx xxxxx x xxxxxxxx chemickou strukturou xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx jsou xxxxxxxx:

1. Xxxxx xxxxxxxxxxx xxxxxxxxxxx (xxxx. erytropoetin (XXX), xxxxxxxxxxx (xXXX), xxxxxxxxxxxxx xxxxxxx vyvolávajícího xxxxxxx (XXX), methoxypolyethylenglykol-epoetin xxxx (XXXX), peginesatid /Hematide/);

2. Xxxxxxxxxxxxxxxxxx (CG) x Xxxxxxxxxxxx hormon (XX) x xxxxxx uvolňující xxxxxxx u xxxx;

3. Xxxxxxxxxxxxxx x xxxxxx xxxxxxxxxx xxxxxxx;

4. Růstový xxxxxx (XX) a xxxx xxxxxxxxxx xxxxxxx x insulinu xxxxxxx xxxxxxx faktor-1 (XXX-1).

Xxxxx xxxx jsou zakázány xxxxxxxxxxx růstové faktory:

Fibroblastové xxxxxxx xxxxxxx (FGFs), xxxxxxxxxxxx xxxxxxx xxxxxx (XXX), xxxxxxxxxx xxxxxxx xxxxxxx (XXX), xxxxxxx xxxxxx xxxxxxxx z xxxxxxxx destiček (PDGF) x vaskulárně-endoteliární xxxxxxx xxxxxx (XXXX), xxxxxx xxxx xxxxxxxxx xxxx xxxxxxx xxxxxxx ovlivňující xxxxxxx xxxx xxxxxxxxx xxxxxxxx xxxxx, xxxxx x xxxxxx, krevní xxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxxx nebo xxxxxxxxxxx xxxx svalových xxxxxx;

x xxxxx xxxxx x podobnou chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.

S3. XXXX2- XXXXXXXX

Xxxxxxx beta-2 xxxxxxxx, xxxxxx všech xxxxxxxxxx xxxxxxxxx xxxxxxx (xxxx. x- x x-), xxxx xxxxxxxx kromě xxxxxxxxxxx xxxxxxxxxxx (xxxxxxxxx 1600 mikrogramů xx 24 xxxxx), inhlalačního xxxxxxxxxxx (xxxxxxxxx xxxxxx xxxxx 54 mikrogramů xx 24 hodin) x xxxxxxxxxxx, pokud xxxx podány x xxxxxxxx x xxxxxxx x xxxxxxxxxxx léčebným xxxxxxx xxxxxxx.

Xxxxxxxxxx xxxxxxxxxxx x xxxx x xxxxxxxxxxx xxxxx xxx 1000 xx/xx x xxxxxxxxxx xxxxxxxxxxx x xxxx v koncentraci xxxxx xxx 40 xx/xx xxxxxx xxxxxxxxxx xx xxxxxxxxx terapeutické xxxxxxx, ale xxxx xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxx, pokud xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, xx xxxxxxxxxx xxxxxxxx xxx xxxxxxxx užíváním terapeutické xxxxxxxxx xxxxx xxxxx xxx výše xxxxxxx xxxxxxx.

X4. HORMONOVÉ X XXXXXXXXXXX XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Inhibitory xxxxxxxx, xxxxxxxxxx:

Xxxxxxxxxxxxxxxx, xxxxxxxxxx, androsta-1,4,6-trien-3-17-dion (xxxxxxxxxxxxxxxxx), 4-xxxxxxxxx-3,6,17-xxxxx (6-oxo), xxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxx xx x omezením xxxxx xx xx.

2. Selektivní xxxxxxxxxx estrogenových receptorů (XXXX), xxxxxxxxxx:

Xxxxxxxxx, tamoxifen, xxxxxxxxx, xxx xx x omezením pouze xx xx.

3. Ostatní xxxxxxxxxxxxxx xxxxx xxxxxxxxxx:

Xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, xxx xx x xxxxxxxx xxxxx xx ně.

4. Xxxxx modifikující xxxxxx xxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxx, xxx xx x omezením pouze xx xx.

5. Xxxxxxxxxxx xxxxxxxxxx:

x) Xxxxxxxx;

x) Receptor xxxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx /Peroxisome Proliferator Xxxxxxxxx Receptor δ (XXXXδ) agonists/ (xxxx. XX 1516) a Xxxxxxxx xxxxxxxxxxxxxxx xxx xxxxxxxxxx XXX x xxxxxxxxxxx x XXXX xxxxx /PPARδ-AMP-activated protein xxxxxx (AMPK) xxxx xxxxxxxx/ (xxxx. XXXXX)

X5. XXXXXXXXX X OSTATNÍ XXXXXXXXX LÁTKY

Maskovací látky xxxx xxxxxxxx. Xxxxxxxx:

Xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxx. xxxxxxxx, xxxxxxxxxx podání xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx x xxxxxxxxx), xxxxxxxxxx x další xxxxx x xxxxxxxxx biologickými xxxxxx. Xxxxxxx xxxxxx xxxxxxxxxxxx xxx xxxxx xxxxxxxx není xxxxxxxx.

Xxxxxxxxx xxxxxxxx:

Xxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxx xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx, thiazidy (xxxx. xxxxxxxxxxxxxxxxxx, hydrochlorothiazid, xxxxxxxxxxxxx), xxxxxxxxxx, vaptany (xxxx. tolvaptan) a xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx (xxxxx xxxxxxxxxxxx, xxxxxxxxx x lokálního xxxxxx xxxxxxxxxxx x xxxxxxxxxxxx, které xxxxxx xxxxxxxx).

Xxx xxxxxxx (Xxx Xxxxxxx, případně Xxxx Xxxxxx) xxxxxxxxxxx xxxxxxxx xxxxx se stanoveným xxxxxxxx xxxxxxx (tj. xxxxxxxxxx, xxxxxxxxxx, katin, xxxxxxx, xxxxxxxxxxxx x xxxxxxxxxxxxx) ve spojení x xxxxxxxxxx nebo xxxxx xxxxxxxxx látkou xx xxxxxxxxxx xxxxxxx xxxxxxxxxx Xxxxxxxxxxxx výjimky xx tuto xxxxx xxxxx x té, xxxxx již xxxx xxxxxxx xx xxxxxxxxxx xxxx jinou xxxxxxxxx xxxxx.

XXXXXXXX METODY

M1. XXXXXXXXXX X KRVÍ A XXXXXXXX XXXXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Xxxxxx xxxx xxxxxxxxxxxxx jakéhokoliv xxxxxxxx xxxxxxxxx, xxxxxxxx (xxxxxxxxx) xxxx heterologní krve xxxx xxxxxxxxx krvinek x xxx podobných xxxxxxxx xxxxxxxxxxx xxxxxx xx oběhového xxxxxxx.

2. Xxxxx xxxxxxxxx xxxxxxxx, xxxxxxx xxxx xxxxxxx xxxxxxx, xxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxx produkty (xxxx. xxxxxx xxxxxxxx založené xx xxxxxxxxxxx, mikroenkapsulované xxxxxxxxxxx), perfluorochemikálie x xxxxxxxxxxx (RSR13), ale xx s xxxxxxxx xxxxx xx xx. Xxxxxxxxxxxx xxxxxxxx zakázána xxxx.

3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx xxxx x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx chemickými xxxxxxx.

X2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Xxxxxxxxx, nebo pokus x podvod, xx xxxxxx xxxxxxx xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx při Xxxxxxxxx xxxxxxxx. Xx xxxxxxxx xxxxxx a/nebo úpravu (xxxx. proteázami) moči, xxx xx s xxxxxxxx xxxxx na xx.

2. Xxxxxxxxxx xxxxxx x/xxxx xxxxxxx xxxx xxx 50 ml xx 6 xxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxxx v xxxxxxx xxxxxxxxxxxx xxxxxxx xxxx xxxxxxxxxx vyšetřovacích xxxxx.

X3. XXXXXX XXXXXX

X xxxxxx xxxxxxxxxx xx xxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxx xxxxxxxxxxx:

1. Xxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxx xxxx jejich analogů;

2. Xxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx.

XXXXX X XXXXXX XXXXXXXX XXX XXXXXXX

Xxxxx xxxxxxxxx X0 až S5 x X1 až X3 xxxxxxxxx výše xxxx Při Soutěži xxxxxxxx x xxxxxxxxxxx xxxxxxx:

XXXXXXXX XXXXX

X6. XXXXXXXXXXX

Xxxxxxx xxxxxxxxxxx včetně xxxxx xxxxxx xxxxxxxxxx optických xxxxxxx (např. x- x x-) xxxx xxxxxxxx, s výjimkou xxxxxxxx imidazoiu v xxxxxxx xxxxxx xxxxxxxx xxxxxxx a xxxxxxxxxxx xxxxxxxxxx do Xxxxxxxxxxxxxx xxxxxxxx xxx xxx 2014*.

Xxxxxxxxxxx xxxxxxxx:

(x) Xxxxxxxxxxxx xxxxxxxxxxx:

Xxxxxxxxx, amfepramon, amfetamin, xxxxxxxxxxx, amifenazol, benfluorex, xxxxxxxxxxxxxxx, xxxxxxxxx, fendimetrazin, xxxxxxxxx, xxxxxxxxxxx, fenkamin, xxxxxxxxxxx, xxxxxxxxxxx, fentermin, xxxxxxxxxxxx /4-fenylpiracetam (xxxxxxxx)/, xxxxxxxxxx, xxxxxxxxxxx, xxxxxx, xxxxxxxxxxx, xxxxxxxxxx, mefenorex, xxxxxxxxxxx, xxxxxxxxxxxx (d-), xxxxxxxx, modafinil, xxxxxxxxxxxxxx, x-xxxxxxxxxxxxxxx, xxxxxxxxxx, prolintan.

Stimulancium, xxxxx xxxx výslovně xxxxxxx x xxxxx xxxxxxxx, xx Specifickou xxxxxx.

(x) Specifická stimulancia (xxxxxxxx):

Xxxxxxxxx (epinefrin)****, benzfetamin, xxxxxxxxxxxxxxxxx, efedrin***, xxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx, famprofazon, xxxxxxxxxxx, xxxxxxxxxxx, fenprometamin, xxxxxxxxxx, xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxx), xxxxxxxxxxxx, xxxxx**, xxxxxxx x jeho xxxxxxx (xxxx. xxxxxxxx, xxxxxxxxx, xxxx-xxxxxxxxxxxxxxxxxxxxx), xxxxxxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxx***, metylendioxymetamfetamin, xxxxxxxxxxxx, xxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxx), xxxxxxxxx, xxxxxxxxxxx, oktopamin, xxxxxxxxx (xxxxxxxxxxxxx), xxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxxxx*****, selegilin, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx), xxxxxxxxxxxx, tuaminoheptan x další látky x xxxxxxxx chemickou xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx účinky.

* Xxxxxxxxxxx xxxxx xxxxxxxx do Xxxxxxxxxxxxxx xxxxxxxx 2014 (xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxx) xxxxxx považovány xx Xxxxxxxx látky.

** Xxxxx xx zakázaný xxxxx při koncentraci xxxxx než 5 xxxxxxxxxx v 1 xx xxxx.

*** Xxxxxxx x xxxxxxxxxxxxx jsou xxxxxxxx xxx xxxxxxxxxxx xxxxx xxx 10 xxxxxxxxxx v 1 xx moči.

**** Xxxxxxx xxxxxx xxxxxxxxxx (xxxxxxxxxx) (xxxx. xxxxx, xxxx xxxxxxxx) xxxx xxxx xxxxxx xxxxxxxx s xxxxxxxxx anestetiky xxxx xxxxxxxx.

***** Pseudoefedrin xx xxxxxxx, pokud xxxx xxxxxxxxxxx v moči xx xxxxx než 150 xxxxxxxxxx xx xxxxxxxx.

X7. XXXXXXXXX

Xxxxxxxx je xxxxxxxxxxx:

Xxxxxxxxxxx, dextromoramid, xxxxxxxxx(xxxxxx), xxxxxxxx x xxxx xxxxxxxx, hydromorfon, xxxxxxx, xxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx.

X8. XXXXXXXXXXX

Xxxxxxxx (xxxx. xxxxx, konopí x xxxxxxxxx) nebo xxxxxxxxxx delta9-tetrahydrokanabinol (THC) x xxxxxxxxxxxxxx (např. "Xxxxx", JWH018, JWH073 x XX-210) xxxx xxxxxxxx.

X9. XXXXXXXXXXXXXXXXXXXX

Xxxxxxx xxxxxxxxxxxxxxxxxxxx xxxxxxxx orálně, rektálně, xxxxxxxxxx nebo xxxxxxxxxxxxx xxxxxxxx xxxx zakázané.

LÁTKY XXXXXXXX V XXXXXXXX XXXXXXXX

X1. ALKOHOL

Alkohol (xxxxxx) xx zakázaný xxxxx Xxx Soutěži x xxxxxxxxxxxxx xxxxxxxx. Xxxxxxx xx xxxx provádět xxxxxxxx xxxxxxxx x/xxxx xxxxxxxx xxxx. Xxxxxxx xxxxxxx pro xxxxxxxx xxxxxxxxxxx pravidla xx xxxxxxxxxxxx xxxxxxxxxxx xxxxxxxx x xxxx 0.10 x/x.

• Xxxxxxxxxxxx sport (XXX)

• Karate (XXX)

• Xxxxxxx xxxxxx a xxxxxxxxxxxx (XXX)

• Xxxxxxxxxxx (XX)

• Xxxxxxxxxxx xxxxx (XXX)

• Vodní motorismus (XXX)

X2. BETA-BLOKÁTORY

Pokud není xxxxx určeno, beta-blokátory xxxx zakázány xxxxx Xxx Soutěži x xxxxxxxxxxxxx sportech.

• Xxxxxxxxxxxx xxxxx (XXX)

• Xxxxxxxx (xxxxxxx discipliny) (XXXX)

• Xxxx (IGF)

• Lukostřelba (XX) (xxxxxxxx také Xxxx xxxxxx)

• Lyžování (XXX) - xxxxx xx xxxxxx x xxxxxxxxxxx xxxxxxxx-xxxxx x X-xxxxx, x xxxxxxxxx X-xxxxx a "xxx xxx"

• Xxxxxxx (XXXX, XXX) (xxxxxxxx xxxx Xxxx xxxxxx)

• Xxxxx (XXX)

Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:

Xxxxxxxxxx, xxxxxxxxxx, atenolol, xxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, esmolol, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, levobunolol, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, pindolol, xxxxxxxxxxx, xxxxxxx, timolol, xxx xx x xxxxxxxx xxxxx na xx.

Xxxxxxxxx

Xxxxxx předpis č. 47/2014 Sb. x. x. xxxxx xxxxxxxxx xxxx 20.9.2014.

Právní xxxxxxx x. 47/2014 Xx. x. x. byl xxxxxx právním xxxxxxxxx č. 19/2017 Sb. m. s. x xxxxxxxxx xx 6.4.2017.

Xxxxx xxxxxxxxxxxx xxxxxxxx norem xxxxxx xxxxxxxx xxxxxxxx v xxxxxxxx xxxx aktualizováno, xxxxx xx xxxx xxxxxx xxxxxxxxx xxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx.